1-(3-fluorobenzyl)-4-(hydroxymethyl)-1H-1,2,3-triazole | 952183-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-fluorobenzyl)-4-(hydroxymethyl)-1H-1,2,3-triazole
• 英文别名: 1-[(3-fluorophenyl)methyl]-4-hydroxymethyl-1H-1,2,3-triazole；[1-(3-Fluorobenzyl)-1H-1,2,3-triazol-4-yl]methanol；[1-[(3-fluorophenyl)methyl]triazol-4-yl]methanol
• CAS: 952183-23-2
• 化学式: C₁₀H₁₀FN₃O
• 分子量: 207.207
• InChiKey: ZNHGZPQNCDVONF-UHFFFAOYSA-N

物化性质

• 熔点：
  64-66

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-(3-fluorobenzyl)-4-(hydroxymethyl)-1H-1,2,3-triazole 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以100%的产率得到4-(chloromethyl)-1-(3-fluorobenzyl)-1H-1,2,3-triazole
  参考文献：
  名称：

  1,2,3-三唑姜黄素衍生物通过调节 MAPK/NF-κB/STAT3 信号通路的抗肺癌活性

  摘要：

  像1,2,3一样轻松呼吸：通过将1,2,3-三唑引入姜黄素的活性亚甲基，设计合成了一系列新型三唑姜黄素。生成的二氯取代苯基三唑甲基姜黄素在体外和体内均能有效抑制肿瘤细胞增殖并诱导肺癌细胞死亡，因此可能成为治疗非小细胞肺癌的潜在药物。

  DOI：

  10.1002/cmdc.202100676
• 作为产物：
  描述：

  3-氟溴苄 在 sodium azide 、 copper diacetate 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 、 叔丁醇 为溶剂， 反应 32.0h， 生成 1-(3-fluorobenzyl)-4-(hydroxymethyl)-1H-1,2,3-triazole
  参考文献：
  名称：

  1,2,3-三唑姜黄素衍生物通过调节 MAPK/NF-κB/STAT3 信号通路的抗肺癌活性

  摘要：

  像1,2,3一样轻松呼吸：通过将1,2,3-三唑引入姜黄素的活性亚甲基，设计合成了一系列新型三唑姜黄素。生成的二氯取代苯基三唑甲基姜黄素在体外和体内均能有效抑制肿瘤细胞增殖并诱导肺癌细胞死亡，因此可能成为治疗非小细胞肺癌的潜在药物。

  DOI：

  10.1002/cmdc.202100676

文献信息

• New mono- and bidentate P-ligands using one-pot click-chemistry: synthesis and application in Rh-catalyzed hydroformylation
  作者：Natalia V. Dubrovina、Lutz Domke、Ivan A. Shuklov、Anke Spannenberg、Robert Franke、Alexander Villinger、Armin Börner

  DOI：10.1016/j.tet.2013.07.070

  日期：2013.10

  Three families of new phosphorus ligands have been prepared using the click-chemistry approach proceeding in only two steps and without intermediate P-protection. The methodology allows the high yield production of mono- and bidentate P-ligands, bearing at least one P–O bond. The ligands were tested in the Rh-catalyzed hydroformylation of 1-octene.

  使用点击化学方法已经制备了三个新的磷配体家族，它们仅以两个步骤进行，并且没有中间的P保护。该方法允许高产量生产单 - 和二齿P配体的，带有至少一个P-O键。在Rh催化的1-辛烯的加氢甲酰基化中测试了配体。
• [EN] PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-GATED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN<br/>[FR] MODULATEURS PHARMACOLOGIQUES DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS NAV1.1 ASSOCIÉS À DES DOULEURS MÉCANIQUES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2017147379A1

  公开（公告）日：2017-08-31

  The present invention provides the use of compounds which selectively block the Nav1.1 subtype of voltage-gated sodium (Nav) channels, whose role in nociception and pain has been unexplored. The present invention demonstrates that Nav1.1-expressing fibers are modality specific nociceptors: their activation elicits robust pain behaviors without neurogenic inflammation and produces profound hypersensitivity to mechanical, but not thermal, stimuli. In the gut, high-threshold mechanosensitive fibers also express Nav1.1 and show enhanced toxin sensitivity in a model of irritable bowel syndrome. The present invention provides an unexpected role for Nav1.1 in regulating the excitability of sensory nerve fibers that underlie mechanical pain, and provides methods of screening for other peptides and small molecules that can modulate Nav1.1 channels and their use in treatment of neurological disorders.

  本发明提供了选择性阻断电压门控钠（Nav）通道的Nav1.1亚型的化合物的使用，其在疼痛感知和疼痛中的作用尚未被探索。本发明证明Nav1.1表达的纤维是特定于模态的伤害感受器：它们的激活引起强烈的疼痛行为，没有神经源性炎症，并产生对机械刺激的深度过敏，而不是对热刺激的过敏。在肠道中，高阈值机械敏感纤维也表达Nav1.1，并在肠易激综合征模型中显示出增强的毒素敏感性。本发明提供了Nav1.1在调节感觉神经纤维的兴奋性方面的意外作用，这些感觉神经纤维是机械性疼痛的基础，并提供了筛选其他肽和小分子以调节Nav1.1通道及其在治疗神经系统疾病中的使用的方法。
• RUFINAMIDE AND DERIVATIVES AND THEIR USE IN MODULATING THE GATING PROCESS OF HUMAN VOLTAGE-GATED SODIUM CHANNELS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20150368211A1

  公开（公告）日：2015-12-24

  The present invention provides compounds of formula I or a salt, solvate, or stereoisomer thereof, wherein X is H, or an electron withdrawing group such as a halogen, NH 2 , NO 2 , SO 2 , CN, or a C 1 -C 6 alkyl group; Alk is C 1 -C 3 alkyl; R 1 is H, C 1 -C 6 alkyl, which may be substituted with OH, NH 2 , acyl, sulfonyl, and cyano groups; and R 2 , is C 1 -C 6 alkyl, which may be substituted with OH, NH 2 , acyl, sulfonyl, and cyano groups. Pharmaceutical compositions comprising these compounds and/or rufinamide are also provided. Methods for prevention and treatment of epilepsy disorders such as Lennox-Gastaut Syndrome (LGS), and modulation of voltage-gated sodium (Nay) channels are Nav1.1 channels by administration of these compounds and/or rufinamide are also provided.
• DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170029382A1

  公开（公告）日：2017-02-02

  The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods for prevention and treatment of neurological disorders, including, for example, seizures and seizure disorders, including Lennox-Gastaut Syndrome, Dravet syndrome, epileptic encephalopathies, autism, Familial hemiplegic migraine (FHM), anxiety disorders, including Post-traumatic stress disorder (PTSD), panic disorder and obsessive-compulsive disorder, neuropathic pain, and Rett syndrome by administration of these compounds are also provided.
• US9505727B2
  申请人：——

  公开号：US9505727B2

  公开（公告）日：2016-11-29